Skip to main content
Psychedex
Article

4F-EPH Facts

Stimulant; Phenidate; Dopamine reuptake inhibitor

Description

4F-EPH (4-fluoroethylphenidate) is a synthetic stimulant of the phenidate class. It is the fluorinated structural analog of ethylphenidate, with greater potency at the transporters that recycle dopamine and norepinephrine.[1] It blocks those transporters, raising levels of both neurotransmitters and producing stimulation and euphoria.[2]

Subjective effects include stimulation, euphoria, focus, and sociability enhancement. More euphoric and less purely stimulating than the closely related 4F-MPH, the experience tilts toward recreation rather than function.[3]

4F-EPH carries high addiction liability confirmed by rodent studies,[4] and no controlled toxicity data or lethal dose have been established.[3] Cardiovascular stress is the primary acute risk[5]: tolerance to euphoria builds faster than tolerance to that strain, so redosing escalates physical danger while the reward fades.[6]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight5 – 10 mgCommon10 – 15 mgStrong15 – 30 mgHeavy30+ mg

Starts in 10 – 25 minLasts 5 – 6 hoursAfter-effects 4 – 12 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Moderate
Psychological dependence
Moderate
Withdrawal
Mild
Compulsive redosing
Moderate

Tolerance

Builds
Moderate
Fully resets after
10 days
Carries over to
amphetamine; cocaine; methylphenidate; ethylphenidate; 4F-MPH

Effectslikely at a common dose

Perception
none likely · 6 possible
Body
Appetite suppression; Insomnia; Pupil dilation; Stimulation; Wakefulness; +16 possible, including Heart rate perception changes, Vasoconstriction, Dehydration sensation
Thinking
Cognitive euphoria; +10 possible, including Compulsive redosing urge, Cognitive dysphoria
Feeling
Euphoria; +6 possible, including Anhedonia, Anxiety, Depression
Self
none likely · 7 possible, including Craving, Ego inflation, Compulsive repetitive behavior
Time
none likely · 1 possible
Awareness
Sustained attention (vicara); +1 possible

Who shouldn't take it

Absolute
Cardiovascular disease; Hypertension; Cardiac arrhythmia; History of psychosis; Bipolar disorder; Pregnancy; Lactation; Concurrent MAOI use; Concurrent tramadol use
Relative
Seizure disorder; Hepatic impairment

Combinations62 recorded

Lethal (2)
Ibogaine; Tramadol
Dangerous (29)
Alpha-2 adrenergic receptor antagonist; Amphetamines; Benzodiazepines, Barbiturates; Ephedrine, Pseudoephedrine; Local anesthetics; MAOIs; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; SSRIs; Stimulants; Anticholinergics; Antipsychotics; Buspirone; Caffeine; Dopamine agonists; DXM; GHB, Baclofen; GHB, GBL; Ketamine, DXM, PCP; Lithium; NSAIDs; and 5 more, see full page
Caution (28)
See full page: psychedex.org/substances/4f-eph
Not graded (3)
Not listed never means safe.

Seek help immediately if

  • Chest pain; racing, pounding, or irregular heartbeat
  • Very high body temperature; heavy sweating; hot, flushed skin
  • Severe agitation, paranoia, panic, or confusion
  • Severe headache; muscle rigidity or twitching
  • Seizures
  • Signs of stroke — face drooping, one-sided weakness, slurred speech
  • Difficulty breathing; collapse or unconsciousness

What to do

  1. Call emergency services for chest pain, overheating, seizure, or unresponsiveness
  2. Move them to a cool, quiet place and reduce stimulation
  3. Cool the body — remove excess clothing, apply cool damp cloths, fan them
  4. Keep them calm; reassure — panic worsens the cardiovascular strain
  5. If seizing, protect from injury (don't restrain); recovery position afterward
  6. Monitor breathing and be ready to give rescue breaths / CPR

Most stimulant overdoses settle with cooling, a calm environment, and time. The medical danger is hyperthermia, cardiac events (arrhythmia, heart attack, stroke), and seizures — get help immediately if any appear.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^McLaughlin G, Morris N, Kavanagh PV, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Murphy B, Walther D, Partilla JS, Baumann MH, Brandt SD (2017) Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers — Drug Testing and Analysis doi:10.1002/dta.2167
  2. [2]
    ^Luethi D, Kaeser PJ, Brandt SD, Krähenbuhl S, Hoener MC, Liechti ME (2018) Pharmacological profile of methylphenidate-based designer drugs — Neuropharmacology doi:10.1016/j.neuropharm.2017.08.020
  3. [3]
    ^abCorkery JM, Schifano F (2022) First Death Involving 4-Fluoroethylphenidate (4F-EPH): Case Report, User Experiences, and Review of the Related Literature — Academic Forensic Pathology doi:10.1177/19253621221142480
  4. [4]
    ^Kim MG, Min HK, Won SS, Lim SK, Jung KK (2026) Discriminative stimulus, rewarding, and reinforcing effects of 4-Fluoroethylphenidate in rodents — Psychopharmacology doi:10.1007/s00213-026-07026-7
  5. [5]
    ^Spiller HA, Hays HL, Aleguas A (2013) Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. — CNS Drugs doi:10.1007/s40263-013-0084-8
  6. [6]
    ^Liechti ME (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling — Swiss Medical Weekly doi:10.4414/smw.2015.14043
Print version
Report an issue